Hamadani Mehdi, Benson Don M, Lin Thomas S, Porcu Pierluigi, Blum Kristie A, Devine Steven M
Department of Internal Medicine, Division of Hematology-Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Eur J Haematol. 2008 Dec;81(6):425-31. doi: 10.1111/j.1600-0609.2008.01146.x. Epub 2008 Sep 4.
The transformation of follicular lymphoma (FL) to high-grade histology occurs in up to 70% of patients. The role of hematopoietic stem cell transplantation (HSCT) in transformed FL is poorly defined. Twenty-four FL patients with histologically confirmed transformation to diffuse large B-cell lymphoma underwent unpurged autologous HSCT at our institution. Their median age was 56 yr. The median number of prior chemotherapies was 2 (range 1-6). Thirteen patients had residual nodal disease measuring more than 2 cm and four patients had bulky disease at the time of HSCT. Six patients had refractory disease at transplantation. At a median follow-up of 38 months, 3-yr progression-free survival following autologous HSCT was 40%. The 3-yr overall survival was 52%. The cumulative incidence of relapse and non-relapse mortality rate was 41% and 25%, respectively.
高达70%的滤泡性淋巴瘤(FL)患者会发生组织学转化为高级别组织学类型的情况。造血干细胞移植(HSCT)在转化型FL中的作用尚不明确。24例经组织学确诊转化为弥漫性大B细胞淋巴瘤的FL患者在我们机构接受了未进行净化处理的自体HSCT。他们的中位年龄为56岁。既往化疗的中位次数为2次(范围1 - 6次)。13例患者在HSCT时存在直径超过2 cm的残留淋巴结疾病,4例患者有大包块病变。6例患者在移植时患有难治性疾病。中位随访38个月时,自体HSCT后3年无进展生存率为40%。3年总生存率为52%。复发的累积发生率和非复发死亡率分别为41%和25%。